Unveiling the Anticancer Mechanisms of Isorhamnetin: A Mini Review

Md Anisur Rahman; Md. Nasimul Haque  Shipon; Mst. Sumaia Akter; Md. Nazmus  Sakib; Md. Farid Uddin; Taposy Rahman; Md. Sakib Al Hasan

doi:10.71193/jmct.20250002

Authors

Md Anisur Rahman Islamic University, Kushtia-7003, Bangladesh. Author https://orcid.org/0009-0004-6382-5867
Md. Nasimul Haque Shipon Gopalganj Science and Technology University, Gopalganj 8100 Author https://orcid.org/0009-0001-7693-303X
Mst. Sumaia Akter Gopalganj Science and Technology University, Gopalganj 8100 Author https://orcid.org/0009-0000-9018-4664
Md. Nazmus Sakib University of Dhaka, Dhaka-1000, Bangladesh Author https://orcid.org/0009-0001-1590-0154
Md. Farid Uddin Jahangirnagar University, Savar, Dhaka-1342, Bangladesh Author https://orcid.org/0009-0000-0099-4912
Taposy Rahman Jahangirnagar University, Savar, Dhaka-1342, Bangladesh Author https://orcid.org/0009-0009-9137-3729
Md. Sakib Al Hasan Gopalganj Science and Technology University, Gopalganj 8100 Author https://orcid.org/0009-0004-7560-4041

DOI:

https://doi.org/10.71193/jmct.20250002

Keywords:

Apoptosis, Cancer, flavonoid, Isorhamnetin, Proliferation

Abstract

Isorhamnetin (ISO), a flavonoid, exhibits significant anticancer properties; however, no review has been conducted on its anticancer activity. This mini-review evaluates the anticancer potential of ISO by summarizing its mechanisms of action based on studies from PubMed, Google Scholar, ScienceDirect and Web of Science. Research on breast, colon, lung, colorectal, gastric, prostate, skin, and gallbladder models, both in vitro and in vivo, supports ISO's anticancer properties. This review highlights its mechanisms of function, including cell cycle arrest, apoptosis induction, and inhibition of key oncogenic pathways such as mitogen-activated protein kinase (MAPK), epithelial-mesenchymal transition (EMT) and phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR). ISO also enhances reactive oxygen species (ROS) production, modulates mitochondrial pathways, and reduces metastasis by inhibiting matrix metalloproteinases (MMPs). Further research is needed on ISO’s pharmacokinetics and clinical efficacy to establish this as an anticancer agent.